<DOC>
	<DOCNO>NCT00329251</DOCNO>
	<brief_summary>The purpose study determine whether immunization schedule beneficial HIV-infected patient CD4 recount 500 cells/mm3 undetectable viral load .</brief_summary>
	<brief_title>Study Influence Vaccination HIV Viral Load Immunologic Responses Against HIV</brief_title>
	<detailed_description>As HIV-infected patient consider immunocompromised , generally recommend receipt appropriate vaccine . However data conflict concern potential harmful effect follow administration commercial vaccine HIV-infected patient . Transient increase ( “ blip ” ) viral load describe associate single dose vaccine , potential risk develop resistance HAART . On hand , describe patient blips increase HIV-specific immune response , may help improve viral control . Comparison : We perform clinical trial evaluate effect vaccination program successfully treat HIV-infected adult HAART compare placebo .</detailed_description>
	<criteria>Age &gt; 18 year Asymptomatic HIV infection CD4 &gt; 500/mm3 &gt; 6 month prior inclusion CD4 nadir &gt; 300/mm3 Being HAART &gt; 1 year prior inclusion Viral load &lt; 200 copies/mL &gt; 6 month prior inclusion Viral load previous treatment &gt; 5000 copies/mL Informed consent Pregnant woman Basal creatinine &gt; 2.5 mg/dL Allergy either vaccine ingredient Chronic hepatitis B GOT/GPT &gt; 250 IU/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>HIV</keyword>
	<keyword>Viral load</keyword>
	<keyword>Vaccines</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>